Skip to main content

Table 1 Demographic and clinical baseline characteristics

From: Myocardial triglycerides in cardiac amyloidosis assessed by proton cardiovascular magnetic resonance spectroscopy

  Amyloidosis
(n = 11)
Controls
(n = 11)
P-value
Age (years) 60.5 ± 11.4 62.9 ± 8.9 0.57
Male (%) 8 (73) 8 (73) 1.0
BMI (g/m2) 24.3 ± 2.9 24.2 ± 4.6 0.94
AL-Amyloidosis 7 (64)
Disease duration (years) 2.19 ± 2.1
Comorbidities
 Diabetes, n(%) 1 (9) 0 (0) 0.31
 Hypertension, n(%) 4 (36) 5 (45) 0.66
 CAD, n(%) 0 (0) 0 (0) 1.0
 Previous stroke, n(%) 1 (9) 0 (0) 0.31
 Class NYHA III-IV n(%) 2 (18) 0 (0) 0.14
Biochemical
 Cholesterol (mmol/L) 5.9 ± 3.2 5.6 ± 1.0 0.794
 HDL (mmol/L) 1.3 ± 0.5 1.5 ± 0.4 0.187
 Non-HDL (mmol/L) 4.5 ± 3.4 4.0 ± 1.0 0.664
 LDL (mmol/L) 2.7 ± 1.2 3.3 ± 0.8 0.234
 Triglycerides (mmol/L) 2.5 ± 2.9 1.7 ± 0.9 0.358
 NT-proBNP (ng/L) 1287 ± 1304
 Creatinine (μg/dL) 110 ± 33.9
Treatment
 Stem cell transplantation 4 (36)
 Chemotherapy 7 (64)
 Green tea 3 (27)
  1. AL amyloid light-chain, BMI body mass index, CAD coronary artery disease, GFR glomerular filtration rate, HDL high density lipoprotein, LDL low density lipoprotein, NYHA New York Heart Association, NT-proBNP N-terminal prohormone of brain natriuretic peptide-levels